

07:06 11 Mar 2019

Arecor appoints ex-IXICO CFO Susan Lowther as its new finance chief

Diabetes drug developer Arecor has appointed Susan Lowther as its new chief financial officer.

Lowther has "significant experience" in the life sciences industry, Arecor said, having previously been the finance boss of AIM-listed IXICO PLC (LON:IXI) until December last year.

She has also been the chief bean counter for French cancer diagnostics specialist Novacyt, RiboTargets and BioWisdom, a data analysis firm which was acquired by Instem PLC (LON:INS) back in 2011.

WATCH: Accor strengthens team with appointment of experienced CFO Lowther started her career at British Gas before moving on to work for US biotech giant Monsanto.

"I am delighted that Susan is joining the Arecor team," said chief executive Sarah Howell.

"She brings a depth of financial and business expertise that will help us to deliver our ambitious growth plans.

"Following the completion of our successful capital raise last year we are well positioned to leverage our proprietary formulation platform in the development of our clinical products and in technology partnerships with pharmaceutical or biotechnology companies."

Lowther added: "This is an exciting time to join Arecor and become part of an innovative and ambitious team."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and

Share Information

Code: ARECO
Listing: PRIVATE-UK
Sector: Pharma & Biotech
Website: arecor.com

Company Synopsis:

Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to (i) develop a portfolio of proprietary products for diabetes care and (ii) deliver superior reformulations of its partners proprietary products.

action@proactiveinvestors.com

agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).